2026 BD opportunity scan for Beijing Danqing Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals

2026 BD opportunity scan for Beijing Biotech: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for BeBetter Med, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bcy Pharm Co, Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bayer Healthcare Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bavarian Nordic A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bausch Health Americas, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale

2026 BD opportunity scan for Bambusa Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Avistone Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ratio

2026 BD opportunity scan for Ausper Biopharma Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Atea Pharmaceuticals, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for argenx SE: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.